NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) An
Post# of 154
(Total Views: 113)
Posted On: 11/07/2023 3:53:18 PM
NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Q3 2023 Financial Results, Operating Highlights
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., today released its third quarter 2023 financial results and provided recent operating highlights for its ALS clinical program. Among the highlights, the company reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients treated with CNM-Au8(R) in the RESCUE ALS open-label extension trial. “We are pleased to be approaching a meaningful regulatory discussion with the U.S. Food and Drug Administration (‘FDA’) later in the fourth quarter to elucidate key next steps in our ALS regulatory submission of CNM-Au8,” said Rob Etherington, president and CEO of Clene. “We are hopeful that the consistent survival, delayed time to clinical worsening and strong safety profile with CNM-Au8 treatment from two phase 2 independent trials is sufficiently compelling for FDA to consider an accelerated path forward. The unmet need remains high for treatments to improve and extend life for patients living with this highly debilitating and rapidly progressive condition.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., today released its third quarter 2023 financial results and provided recent operating highlights for its ALS clinical program. Among the highlights, the company reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients treated with CNM-Au8(R) in the RESCUE ALS open-label extension trial. “We are pleased to be approaching a meaningful regulatory discussion with the U.S. Food and Drug Administration (‘FDA’) later in the fourth quarter to elucidate key next steps in our ALS regulatory submission of CNM-Au8,” said Rob Etherington, president and CEO of Clene. “We are hopeful that the consistent survival, delayed time to clinical worsening and strong safety profile with CNM-Au8 treatment from two phase 2 independent trials is sufficiently compelling for FDA to consider an accelerated path forward. The unmet need remains high for treatments to improve and extend life for patients living with this highly debilitating and rapidly progressive condition.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)